Patrick VILLANI

Professeur des Universités en Thérapeutique-Praticien Hospitalier avec une valence hospitalière en Médecine Interne et Biologie du Vieillissement, option Médecine Interne (53.01). Faculté de Médecine de Marseille ; AP-HM, Hôpital Sainte Marguerite, Service de Médecine Interne et Thérapeutique, Chef de service depuis 2007

Aix-Marseille University

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Research Cancer Research professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Patrick Villani is a Professor of Therapeutics at Aix-Marseille University and serves as the Head of the Internal Medicine and Therapeutics Department at Hôpital Sainte Marguerite, a position he has held since 2007. His research areas include the long-term effects of COVID-19, access to healthcare for aging populations, and the management of multimorbidity in older patients. His recent publications address critical topics such as biomarkers in antisynthetase syndrome and the management of treatment-related side effects in cancer patients.

Articles (13)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

Aurélie Bocquier

Université de Lorraine

FRANCE

View details

ariane pille

Institut Paoli-Calmettes

FRANCE

View details

Anna Zaytseva

Université libre de Bruxelles

BELGIUM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Patrick VILLANI

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Persistent COVID-19: a case report of an immunocompromised patient and a literature review.

Access to care for aging former workers living in an immigrant hostel

Anti-Jo-1 autoantibodies: biomarkers of severity and evolution of the disease in antisynthetase syndrome.

[Tagravpa: Help table and grid for identifying the risk of aggravation and early rehospitalization of elderly persons 75 years and older referred to emergency departments and/or hospitalized in care units].

Tocilizumab versus anakinra in COVID-19: results from propensity score matching.

Quality of life in older French long-term lung cancer survivors: VICAN5 national survey.

[Medication reconciliation: Interests and limits].

Prevention of aromatase inhibitor–induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer

In Vivo Studies on Radiofrequency (100 kHz-300 GHz) Electromagnetic Field Exposure and Cancer: A Systematic Review.

Une splénomégalie fébrile

General practitioners' attitude towards cooperation with other health professionals in managing patients with multimorbidity and polypharmacy: A cross-sectional study.

Geriatric syndromes in a centenarians population

Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer

Collaborators (3)

Aurélie Bocquier

ariane pille

Anna Zaytseva

Make your next move.